TRex Bio (NASDAQ:TRXB) Announces Quarterly Earnings Results

TRex Bio (NASDAQ:TRXB – Get Free Report) posted its earnings results on Friday. The company reported ($10.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($9.37), Zacks reports.

TRex Bio Price Performance

TRXB traded down $0.43 during trading on Friday, reaching $13.67. The stock had a trading volume of 62,668 shares, compared to its average volume of 106,799. TRex Bio has a one year low of $12.50 and a one year high of $16.56.

Insiders Place Their Bets

In other news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the company’s stock in a transaction on Tuesday, October 13th. The stock was purchased at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the purchase, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. This trade represents a 15.29% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of TRex Bio in a research report on Tuesday, November 3rd. They set an “overweight” rating for the company. JPMorgan Chase & Co. initiated coverage on TRex Bio in a research report on Tuesday, November 3rd. They issued an “overweight” rating and a $20.00 price objective on the stock. Stifel Nicolaus started coverage on TRex Bio in a research note on Tuesday, November 3rd. They set a “buy” rating and a $39.00 price objective for the company. Zacks Research began coverage on TRex Bio in a research report on Tuesday, November 3rd. They set a “hold” rating for the company. Finally, Wedbush assumed coverage on TRex Bio in a research note on Monday, November 2nd. They issued an “outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $29.67.

Get Our Latest Research Report on TRex Bio

About TRex Bio

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.

Read More

Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.